insidermonkey.comSEP 292 min read$AMGN

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?

Amgen (AMGN) reported positive Phase 3 trial results for dazodalibep in systemic Sjögren’s disease, meeting primary endpoints. Citi reaffirmed a Neutral rating and $405 price target, citing unanswered questions about efficacy and competitive profile. Amgen's Q2 2026 revenue grew 10% YoY to $10.1B, with key growth drivers like TEZSPIRE and UPLIZNA. However, legacy products faced biosimilar erosion, with Prolia and XGEVA sales declining 32% and 34%, respectively.

Original reporting

insidermonkey.com

Published Sep 29, 2026, 1:27 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 29, 2026, 2:48 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? — source image — Source · insidermonkey.com

Decision brief

The 30-second read

$AMGNBullishHigh

Why it matters

The Phase 3 result is a material catalyst that could shift investor sentiment and valuation.

Market read

New trial data provides a fresh trading catalyst for AMGN, with potential upside pending full data release.

What to watch

Biosimilar erosion in Amgen's legacy products could offset gains from the new asset.

Relevance 9/10Novelty 9/10Timing: post-announcement today

Background

Amgen's I&I pipeline is under scrutiny as legacy biologics lose market share to biosimilars.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$AMGNBullishHigh confidence

Context

Amgen announced positive Phase 3 topline results for dazodalibep in systemic Sjögren’s disease.

Expected impact

potential upside as the market prices in the positive trial outcome

Evidence & confidence

Phase 3 success reduces clinical risk for a new I&I asset, but missing details keep investors cautious.

Market effects

Sector

Strengthens the biotech/inflammation sector outlook and may boost peer valuations.

Regional

U.S. biotech stocks could see modest gains in early trading.

Global

Positive data may influence global investors tracking autoimmune therapy pipelines.

Counterpoint

What could challenge this read

If full data reveal modest efficacy, the stock could face pressure despite the headline win.

Key entities

company
Amgen Inc.
Biopharma company reporting the trial results.
analyst
Citi
Reaffirmed neutral rating and $405 price target.

Read at source ← All news

OCT 1

$AMGNMedAI 9/10

Imdelltra extends survival in relapsed small cell lung cancer, Korean investigator says

Amgen's Imdelltra (tarlatamab) showed extended survival in relapsed small cell lung cancer. In the DeLLphi-304 trial, median overall survival was 13.6 months with tarlatamab vs. 8.3 months with chemotherapy. Professor Ahn Myung-ju of Hanyang University Medical Center presented the findings at an Amgen Korea press conference.

koreabiomed.com2 min

SEP 30

$AMGNMedAI 8/10

Is Amgen (AMGN) Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) reported positive Phase 3 trial data for its Sjögren's disease drug, dazodalibep, boosting its autoimmune pipeline. The stock has surged 17.2% in 90 days and 29.3% year-to-date. Analysts debate its valuation, with one model suggesting it's overvalued at $423.64 vs. a fair value of $359.98, while another DCF model estimates it's undervalued at $672.77.

simplywall.st3 min

SEP 30

$AMGNMedAI 9/10

Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody

Amgen's phase 2 trial of daxdilimab showed a 6-point reduction in lupus severity at the lower dose, meeting primary and secondary endpoints. The study involved 72 patients with discoid lupus. Amgen plans to advance daxdilimab into registrational development, acquired from Horizon Therapeutics in 2023. The drug previously failed in systemic lupus trials.

fiercebiotech.com2 min

SEP 29

$AMGNLowAI 9/10

Amgen (AMGN), What Is Behind The Fresh Attention?

Amgen (AMGN) reported positive Phase 3 trial data for dazodalibep in Sjögren's disease, boosting its autoimmune pipeline. Shares rose 15.5% in 90 days and 27.6% year-to-date. Analysts debate valuation, with some arguing it's 16.2% overvalued at $418.13, while others see potential in future cash flows. Legacy drug erosion and competitive pressures are key risks.

finance.yahoo.com3 min

SEP 27

$AMGNMedAI 8/10

Why Amgen’s Pipeline Just Got More Interesting

Amgen's experimental drug dazodalibep met the main goal in a late-stage trial for Sjögren's disease, showing significant improvements. The company generated $36.8B in 2025 revenue and invested $7.3B in R&D. Success could strengthen its pipeline as it faces patent pressures on products like Prolia. Amgen's shares rose 4% post-announcement.

finance.yahoo.com2 min

SEP 26

$AMGNLow

Amgen Sells Deerfield Campus for $151M Sale

Amgen sold its Deerfield campus for $151M in a sale-leaseback deal, retaining one building while Fortune Brands Innovations occupies the other two. The buyer is an entity affiliated with Mesirow. The property has changed hands multiple times in recent years. Sale-leasebacks are a common strategy for companies to unlock capital from real estate.

hoodline.com2 min